Seleccione otro país
Bienvenido a Lyxor EspañaWelcome
Por favor, lea la información importante aquí incluida antes de continuar a nuestra página web

Información relevante 

Los Lyxor ETFs presentados en la página web de lyxoretf.com, pueden ser objeto de restricciones en lo que respecta a la inversión por determinadas personas o en determinados países, en virtud de las distintas regulaciones nacionales aplicables a dichas personas o en dichos países. Cualquier persona que acceda a esta página web desde una jurisdicción en la cual se aplican dichas restricciones tiene que informarse al respecto y observar dichas restricciones. Por consiguiente, le corresponde a usted asegurarse de que, efectivamente está autorizado a invertir en los Lyxor ETFs presentados en esta página web. Invirtiendo en estos productos, usted garantiza a Société Générale que está efectivamente autorizado a invertir. Inversores españoles se deben dirigir a www.lyxoretf.es

La información contenida en esta página web no constituye una oferta o invitación para adquirir o vender los productos aquí descritos a personas sometidas a  jurisdicciones donde:

(a) dicha oferta o invitación no esté autorizada;
(b) Lyxor Asset Management no esté cualificada para hacer dicha oferta o invitación;
(c)  sea ilícito hacer dicha oferta o invitación.

Los ETFs referidos en esta página web no han estado y no estarán registrados conforme al U.S Securities Act de1933, por lo tanto, no pueden ser ofertados ni vendidos en los EE.UU sin registro previo o solo en caso de excepción de registro conforme al  al Securities Act. Por consiguiente, los ETFs listados en esta página web no pueden ser vendidos a “U.S persons”, ni transferidos a los Estados Unidos a menos que dicha transacción esté sujeta a los requisitos de registro conforme a la ley Americana.

Esta página web es de carácter comercial y no de carácter legal. No se garantiza la exactitud, exhaustividad o pertinencia de la información aunque ha sido establecida a partir de fuentes consideradas como fiables.
La información presentada en esta página web se basa en información de mercado constada en un momento dado que puede variar con posterioridad a su publicación. El valor de reembolso de los Lyxor ETFs puede ser inferior al montante de la inversión inicial. En el peor de los casos, los inversores podrían perder hasta la totalidad de su inversión, por lo que se recomienda a los inversores consultar la sección« factores de riesgo » del folleto del producto. El precio de algunos Lyxor ETFs puede ser sensible a riesgos de tipo de cambio entre la cotización del ETF y/o la divisa del índice y/o la divisa del componente del índice.

Todos los LyxorETFs presentados en esta página web han sido aprobados por la “Autorité des Marchés Financiers (AMF)” y son objeto de un folleto aprobado por la AMF y pasaporteado en la CNMV conforme a la Directiva 2003/71/CE. Dichos folletos están disponibles en esta página Web.

La documentación relativa a los Lyxor ETFs preverá métodos de ajuste y de sustitución para tener en cuenta que consecuencias tendría cualquier suceso extraordinario que afecte a uno o varios de los subyacentes de estos productos.

Antes de invertir en un Lyxor ETF, usted debe hacer su propia valoración del riesgo desde un punto de vista legal, fiscal y  contable, sin depender exclusivamente de la información que le proporcionamos y consultando, si lo estima necesario, sus propios asesores en la materia o cualquier otro asesor independiente.

El inversor de ETFs estará expuesto a los siguientes factores de riesgo: Riesgo de pérdida del capital invertido, al no existir ninguna garantía, como consecuencia de un movimiento desfavorable del Índice de Referencia, Riesgo de que el objetivo de gestión solo se cumpla parcialmente, Riesgo de contrapartida como resultado de la utilización de los instrumentos financieros (OTC) formalizados con un establecimiento de crédito. Se recomienda a los inversores que consulten la sección del folleto antes de invertir.

En la medida en que cumpla con la legislación aplicable, ninguna entidad del Grupo Société Générale acepta responsabilidad alguna por las consecuencias financieras o de cualquier otra naturaleza que resulten de la inversión en este producto.

20 abr 2020

How Artificial Intelligence is reshaping our economy

global green

In our latest guest blog, futurist Martin Ford discusses the latest developments of the index underlying Lyxor’s Robotics and AI ETF launched in 2018. He believes AI has huge potential to transform all sectors of our economy, and that this is well reflected in the index holdings.



Martin Ford is a futurist focusing on the impact of artificial intelligence and robotics on society and the economy. He is author of the book “Rise of the Robots: Technology and the Threat of a Jobless Future”, and acts as a consultant to Société Générale, the index designer.

The Rise of the Robots index

The SG Rise of the Robots Index has a broad focus on identifying publicly-traded companies which are likely to benefit from the emerging revolution in AI and robotics. While the index includes a comprehensive selection of companies innovating in areas directly related to AI and automation, the strategy is really built on the belief that artificial intelligence is rapidly evolving into a kind of utility—a force poised to scale across and transform the entire global economy. So, the index includes companies in a variety of industries outside the tech sector which are able to leverage these technologies in their business models.

AI – a force poised to transform virtually all sectors

There is growing evidence that artificial intelligence is rapidly becoming a systemic technology. For example, in July 2019, Microsoft invested a billion dollars in the San Francisco-based research organisation OpenAI. OpenAI is focused on building truly advanced, or human-level, AI, an endeavor that is likely to take decades.

In the meantime, OpenAI’s research will spawn many practical applications for Microsoft both in its operations and in its cloud computing division, Azure. The integration of powerful AI capability into cloud computing platforms, and the intense competition is this area between the major players Amazon, Microsoft, and Google, is transforming the cloud into the most important conduit for delivering artificial intelligence to virtually every industry sector.

A hybrid index built to evolve with the times

At the end of each calendar year, we update the universe of companies available for inclusion in the Rise of the Robots index. The universe includes stocks we believe are good candidates for index inclusion based on factors such as company strategy and technical focus on AI or robotics. Companies that make it into the index itself are selected algorithmically based on several financial measures including R&D expenditure on net sales, return on invested capital, and 3-year sales growth. Therefore, the index is managed according to a hybrid system where we combine annual judgment on eligible stocks with a purely systematic approach to selecting stocks from that eligible universe.  

Index additions: from cloud computing and 3D printing to remote healthcare and gene sequencing

Companies added in the information technology sector this year include, for example, Cloudera, based in Palo Alto, California.  Cloudera offers a range of software and services geared towards enterprise cloud computing. The company has a strong focus on tools that enable its clients to leverage cloud resources in machine learning and AI applications. 

UK based AVEVA Group, Plc is a leading provider of industrial and engineering software. The company is integrating artificial intelligence capability to enhance productivity for a range of sectors, including chemicals, food processing, life sciences, oil and gas and mining. Elastic, N.V. founded in the Netherlands and now headquartered in Silicon Valley, builds AI-enabled software that enables data search and retrieval.

Companies added in the healthcare and life science sectors include Pennsylvania-based BioTelemetry, Inc, which produces smart devices currently used to remotely monitor over a million cardiology patients. The company is in a strong position to leverage AI to extract important insights from this data.

Gene-sequencing company Illumina, Inc. headquartered in San Diego, CA, is deploying AI and machine learning to search for mutations in the genomes of patients with genetic diseases—an innovation that could eventually lead to treatments. Illumina’s gene sequencing technology was used in January in one of the first attempts to characterise the genome of the coronavirus, which was at the time making its first appearance in Wuhan, China.  Mountain View, CA-based Omnicell Inc makes pharmacy robots designed to fully automate the preparation of medications in hospitals.

Other additions include the Belgian company Materialize NV, which is a global leader in 3D printing, and GEA Group AG, based in Düsseldorf, Germany, that specialises in advanced automation for the food and beverage industries. 

27 new eligible constituents for 2020

In all, the 2020 universe update, which reflects changes in the status and strategies of companies, as well as corporate takeovers and IPOs that occurred during the year, adds 27 new eligible constituents.  The total number of stocks now in the universe is now 248. Of these, 150 are selected systematically for inclusion in the index.

We believe this selection of relevant stocks results in an investment vehicle uniquely positioned to effectively capture the enormous value likely to be generated through the utilisation of AI and robotics across nearly all economic sectors. 

The view from Lyxor

Our $130m+ Lyxor Robotics & AI UCITS ETF is the only ETF of its kind combining human expertise, big data, and fundamental weighting favouring businesses with a proven track record of increasing sales and spending on R&D.1

Unlike many similar available ETFs, the underlying index is designed to capture the full opportunity set of robotics, automation and AI, across sectors. Over 40 of its holdings are unique and not found in peer indices.1

Over a 1-year and 5-year period, the index has outperformed similar indices tracked by comparable ETFs in the European market, while the fund itself has outperformed its ETF peers since its inception in 2018. A large amount of this outperformance came from these unique stocks not found in peer funds.1

Find out more about the ‘Rise of the Robots’ index underlying our ETF

1Source: Lyxor International Asset Management, as of 09/02/2020. Statements about Lyxor credentials vs. peers are based on the European UCITS ETF market only. Peer ETF group selected by Lyxor based on relevant target exposures in the areas of robotics, automation and artificial intelligence. Past performance is not a reliable indicator of future returns.

This article is for informative purposes only, and should not be taken as investment advice. Lyxor ETF does not in any way endorse or promote the companies mentioned in this article. The opinions expressed by Martin Ford are his own, and do not necessarily reflect the views of Lyxor International Asset Management or Societe Generale. Martin Ford is a futurist focusing on the impact of artificial intelligence and robotics on society and the economy. He is author of the book “Rise of the Robots: Technology and the Threat of a Jobless Future”, and acts as a consultant to Société Générale, the index designer. Capital at risk. Please read our Risk Warning below.


Risk Warning

This document is for the exclusive use of investors acting on their own account and categorised either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2014/65/EU. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on www.lyxoretf.com, and upon request to client-services-etf@lyxor.com.

Except for the United-Kingdom, where this communication is issued in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658, this communication is issued by Lyxor International Asset Management (LIAM), a French management company authorized by the Autorité des marchés financiers and placed under the regulations of the UCITS (2014/91/EU) and AIFM (2011/61/EU) Directives. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on www.lyxoretf.com. In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Research disclaimer

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures and disclaimers. Alternatively, visit our global research disclosure website www.lyxoretf.com/compliance.

Conflicts of interest 

This research contains the views, opinions and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on linkedin